Ono Pharmaceutical Co., Ltd. clinical trial pipeline

7 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 4 with minor changes only.

1. Notable

   ONO-4538 Phase II Rollover Study (ONO-4538-98)

   Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027

   Also in this update: Enrollment increased: 59 → 70 participants; Trial sites expanded: 38 → 44 locations

   Ono Pharmaceutical Co., Ltd.·Phase 2· NCT04566380· Registry history of NCT04566380 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

2. Notable

   Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With…Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment · Metastatic Pancreatic Cancer

   Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027

   Ono Pharmaceutical Co., Ltd.·Phase 1· NCT06532344· Registry history of NCT06532344 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

3. Notable

   ONO-2808 · Multiple System Atrophy

   Primary endpoint(s) modified

   Also in this update: Results posted: Oct 6, 2026

   Ono Pharmaceutical Co., Ltd.·Phase 2· NCT05923866· Registry history of NCT05923866 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.